Saturday 17 October 2026 Export CRDL’s income statement to Excel — free account

Cardiol Therapeutics Inc.

CRDL Healthcare Drug Manufacturers Specialty & Generic

In the quarter to June 2026, EPS grew 42.9%, free cash flow grew 10.6% and total debt fell 38.8%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

1.10 0.05 −4.35%

Follow CRDL

Alert me

Market cap: $138.8M
P/E: 0.0×
Fwd P/E: −1.2×
Dividend yield: —
F-score: n/a
Altman Z: 3.42
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 138.76

Revenue —

Net Income (24.38)

Free Cash Flow (17.24)

Net Debt (18.79)

Current Ratio 5.55

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (1.24)

P/S ratio 0.00

P/B ratio 7.28

Past 5Y EPS Growth —

This Y EPS Growth (12.74%)

Next Y EPS Growth 28.72%

Next Y revenue growth (100.00%)

Next 5Y EPS Growth 72.15%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

P/B against its own 10 years 64.56%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	26	22	15	19
Receivables	0	0	0	0
Inventory	—	—	—	—
Other	—	—	—	—
	27	23	17	21

	2023	2024	2025	Q'26
Payables	6	5	2	3
ST’ Debt	—	—	—	—
Other	0	—	2	1
	6	5	4	4

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	4.13%	(31.70%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(5)	(3)	—	—	—
’25	(5)	(3)	(5)	(4)	(17)
’24	(5)	(3)	(6)	(4)	(18)
’23	(7)	(4)	(3)	(5)	(19)
’22	(7)	(3)	(4)	(7)	(21)
’21	(6)	(11)	(5)	(3)	(19)
’20	(2)	(1)	(2)	(2)	(7)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(6)	(3)	—	—	—
’25	(5)	(3)	(5)	(4)	(17)
’24	(5)	(3)	(6)	(4)	(18)
’23	(7)	(4)	(3)	(5)	(19)
’22	(7)	(3)	(4)	(7)	(21)
’21	(6)	(11)	(5)	(3)	(19)
’20	(2)	(1)	(2)	(2)	(7)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.07)	(0.04)	—	—	—
’25	(0.10)	(0.07)	(0.09)	(0.05)	(0.28)
’24	(0.10)	(0.07)	(0.13)	(0.07)	(0.37)
’23	(0.08)	(0.09)	(0.07)	(0.09)	(0.33)
’22	(0.11)	(0.08)	(0.10)	(0.09)	(0.38)
’21	(0.21)	(0.13)	(0.18)	(0.09)	(0.58)
’20	(0.08)	(0.09)	(0.10)	(0.23)	(0.54)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	1.62	1.08	1.75	0.47	0.45	0.82	0.77	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	10.00	3.83	4.96	2.36	1.24	3.12	1.59
People
People	Employees	—	—	—	—	—	11	17	17	18	18
	Revenue/emp, $m	—	—	—	—	—	0.01	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	—	0	—	—	—	—
	Gross margin, %	—	0.00	0.00	0.00	0.00	100.00	0.00	—	—	—
	EBT	—	(1)	(12)	(11)	(16)	(25)	(24)	(21)	(27)	(24)
	EBT margin, %	—	0.00	0.00	0.00	0.00	(40,197.77)	0.00	0.00	0.00	0.00
	Net income	—	0	(12)	(11)	(16)	(25)	(24)	(21)	(27)	(24)
	Depreciation	—	0	0	0	0	0	0	0	0	0
Per share, $
Per share, $	Revenue	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Earnings	—	(0.06)	(0.76)	(0.41)	(0.54)	(0.58)	(0.38)	(0.33)	(0.37)	(0.28)
	Cash flow	—	(0.04)	(0.52)	(0.34)	(0.24)	(0.43)	(0.33)	(0.29)	(0.26)	(0.20)
	Capex	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Free cash flow	—	(0.04)	(0.52)	(0.34)	(0.24)	(0.43)	(0.34)	(0.29)	(0.26)	(0.20)
	Book value	—	0.10	1.07	0.44	0.35	1.41	0.64	0.32	0.25	0.15
	Shares, m	—	23	15	26	30	43	63	64	72	87
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	0.00	—	—	—	—
	P/S	—	—	—	—	—	0.00	—	—	—	—
	P/B	—	—	—	—	—	1.75	—	—	—	—
	EV/Sales	—	—	—	—	—	0.00	—	—	—	—
	EV/FCF	—	—	—	—	—	(1.62)	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	—	(1)	(8)	(9)	(7)	(19)	(21)	(19)	(18)	(17)
	Capex	—	0	0	0	0	0	0	0	0	0
	Free cash flow	—	(1)	(8)	(9)	(7)	(19)	(21)	(19)	(18)	(17)
Balance, $m
Balance, $m	Working capital	—	2	16	11	10	60	40	21	18	13
	Total debt	—	0	0	0	0	0	0	0	0	0
	Net debt	—	(2)	(12)	(5)	(11)	(67)	(46)	(26)	(22)	(15)
	Shareholders’ equity	—	2	16	11	10	61	40	21	18	13
Returns, %
Returns, %	ROA	—	(12.82)	(128.77)	(70.00)	(133.00)	(61.10)	(40.38)	(55.64)	(106.13)	(120.54)
	ROIC	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	—	(14.24)	(125.25)	(76.10)	(149.55)	(70.83)	(47.12)	(68.23)	(137.37)	(156.96)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2021 · latest quarter Jun 2021

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
AKBA Akebia Therapeutics, Inc.	$192.7M	— (loss-making)	— (loss-making)	−21.36% (below 0%: shrinking)	n/m	−88.99% (below 0%: shrinking)	78.78%	(12.88%)	Compare
DERM Journey Medical Corporation	$144.7M	— (loss-making)	91.8×	+23.33% (above 0%: growing)	n/m	−84.08% (below 0%: shrinking)	66.81%	2.46%	Compare
ORGO Organogenesis	$142.8M	— (loss-making)	— (loss-making)	−56.68% (below 0%: shrinking)	n/m	+10.29% (above 0%: growing)	45.90%	(116.54%)	Compare
CRDL Cardiol Therapeutics Inc.	$138.8M	— (loss-making)	— (loss-making)	—	n/m	+10.61% (above 0%: growing)	0.00%	0.00%
OGI Organigram Global Inc.	$131.4M	2.0×	11.4×	+49.28% (above 0%: growing)	n/m	−192.32% (below 0%: shrinking)	39.16%	5.04%	Compare
BGM BGM Group Ltd.	$114.7M	144×	44.9×	−2.59% (below 0%: shrinking)	−85.71% (below 0%: shrinking)	+3.00% (above 0%: growing)	7.12%	0.00%	Compare
PROCF Sofgen Pharma S.A	$114.0M	0.1×	4.0×	+17.28% (above 0%: growing)	n/m	+231.11% (above 0%: growing)	56.09%	36.48%	Compare
CPIX Cumberland Pharmaceuticals Inc.	$113.0M	— (loss-making)	— (loss-making)	−56.28% (below 0%: shrinking)	n/m	−82.78% (below 0%: shrinking)	100.00%	(1,898.20%)	Compare
CLVR Clever Leaves Holdings Inc.	$96.5M	— (loss-making)	— (loss-making)	+5.36% (above 0%: growing)	n/m	+70.31% (above 0%: growing)	(7.46%)	(105.91%)	Compare
Median of peers	$123.0M	2.0×	28.2×	+1.39%	—	−39.89%	51.00%	(6.44%)

All 86 Drug Manufacturers Specialty & Generic stocks →

Cardiol Therapeutics Inc. (CRDL) key facts

Cardiol Therapeutics Inc. (CRDL) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, CRDL traded at $1.10, a market capitalization of $138.8 million.
Return on equity was −157.0% and debt-to-equity 0.00.

Source: company filings (standardised) and stockrow calculations.